Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Sangamo Therapeutics excels in 2022 trials, prioritizes innovative programs

Sangamo Therapeutics had a strong year in 2022, focusing on key programs like CAR-Treg and Fabry disease while making strategic decisions to optimize resources.
Positive trial results and FDA alignment signal progress and potential for future collaborations and advancements in treatments.
Challenges include resource reallocation, endpoint validation, and data transparency, which require careful management and strategic planning.
Overall, Sangamo's performance, strengths, and opportunities position the company well for continued growth and innovation in the biopharmaceutical sector.

Sangamo Therapeutics reports strong Q1 revenue and strategic reorganization

Sangamo Therapeutics is strategically reorganizing to focus on neurology, Fabry, and TX200 CAR-Treg programs, aiming to reduce cash burn and enhance operational efficiency.
The company's emphasis on genomic medicines for chronic pain and neurological disorders highlights its commitment to addressing significant unmet medical needs.
While facing capital constraints, Sangamo is exploring financing options and partnerships to support future growth and innovation, balancing patient benefit and safety in clinical advancements.

Sangamo Therapeutics excels in clinical progress and strategic collaborations

Sangamo Therapeutics demonstrates strong performance in clinical and preclinical programs, backed by a solid financial position and strategic collaborations. Challenges include the need for additional funding and ensuring successful trial execution. Opportunities for growth through expanding partnerships and innovative genomic engineering approaches.

Sangamo shifts focus to neurology, eyes partnerships for growth

Sangamo's strategic shift to neurology shows promise but requires navigating challenges of restructuring and resource reallocation.
The company's financial discipline and focus on operational efficiency aim to ensure self-sustainability until Q3 2024 without additional capital raises.
Progress in innovative therapies like CAR-Tregs and AAV capsid evolution positions Sangamo well for advancements in genomic medicine for neurological disorders.
Exploration of partnerships and monetization opportunities present avenues for growth and strategic advancement in Sangamo's therapeutic programs.

Sangamo Therapeutics excels in neurology advancements and financial stability

Sangamo Therapeutics made significant strides in neurology programs, financial stability, and technology advancements, positioning the company for future growth
Challenges in clinical trial navigation and funding require strategic planning, while opportunities in collaborations and partnerships offer avenues for expansion
Overall, Sangamo's focus on innovation, cost efficiency, and strategic collaborations bode well for its continued success in the neurology and gene therapy space

Sangamo Therapeutics reports positive trial results and lucrative collaborations

Sangamo Therapeutics showcased strong performance in their pipeline with positive trial results and progress in the Fabry disease program.
The company's collaboration agreements and innovative technologies position them well for future growth and revenue generation.
While facing challenges in manufacturing and commercialization, Sangamo has significant opportunities in advancing genomic medicines and expanding therapeutic applications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results. “This quarter, we have continued our focus on advancing our lead programs through clinical execution, regulatory interactions, and collaborations with our partners and investigators. We are pleased that enrollment has completed for Pfizer's lead-in study for the hemophilia A Phase 3 AFFINE trial. Additionall

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format. “Our zinc finger technology has shown the versatility to have broad applications across a diverse range of therapeutic areas and the upcoming presentations at ASGCT will focus on one area of particularly high unmet

Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates. The

Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast

Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, and in vivo genome editing, looks attractive at current levels of $11, after the recent correction of 30% year-to-date. The stock is still around 2x.

Sangamo Therapeutics Stock Looks Attractive At $11

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease conference on April 1, 2021. Sangamo management is expected to participate in a panel discussion at 10 a.m. Eastern Time on April 1, 2021. The event will be webcast live and available via an access link on the Sangamo Therapeutics website in the Investors an

Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease

Biogen

Fate Therapeutics

Gilead Sciences

Johnson & Johnson

Orchard Therapeutics plc - ADR

Sana Biotechnology

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Regenerative Medicine Attracted Record $20 Billion in Funding in 2020

Earlier this month, we discussed that the stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, may trend higher in the near term, based on the company's robust pipeline, and our machine learning analysis. SGMO stock has seen.

What's Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 1/2 PRECIZN-1 study partnered with Sanofi. The Committee's decision to grant Orp

Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease

Genomic medicine collaborations are a valuable method of risk mitigation. They also are a source of funding which can be used to build a deeper pipeline. Sangamo is leveraging many pharmaceutical leaders to help fund an emerging pipeline of owned programs.

Sangamo: Partnering A Path To The Future Of Medicine

The stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation, has seen a 17% drop over the last ten trading days, while it's down 11%.

Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2020 Results - Earnings Call Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights. “We are very pleased with our execution and the progress we made in the challenging year of 2020 during the pandemic, where we advanced our hemophilia A product candidate into a Phase 3 clinical trial with Pfizer, dosed patients in our Phase 1/2 clinical study evaluating our wholly owned produ

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo's Chief Executive Officer. Sangamo also announced today that, effective January 1, 2021, Jason Fontenot, PhD, has been promoted to Chief Scienti

Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer

Beam Therapeutics

Cellectis SA

Calyxt

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

7 CRISPR Stocks for the Future of Medicine

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee's last day of employment will be February 1, 2021. “Sung has contributed significantly to Sangamo's evolution, helping us build a strong cash position to advance proprietary medicines for patients in need as we begin a year with several potential catalysts,” said Sandy

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST. The virtual session will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo we

Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Sangamo: 'Good Companies Get Bought, Not Sold'

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5%

Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?

Vertex Pharmaceuticals

In the Century of Biology, it pays to own the future of curing disease at the root.

CRISPR Gene Editing: Owning the Future of Medicine

Pfizer

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th - 8th. The oral pres

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy

Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the mutant gene tied to diseases such as ALS and Huntington's.

Genomic Medicine: Slowly Moving To All At Once

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. “We are pleased with the clinical execution momentum across our portfolio, including the first patient dosed in the registrational AFFINE study of our investigational hemophilia A gene therapy partnered with Pfizer, as well as dosing of the first two patients in the Phase 1/2 STAAR study evaluating our Fabry

News for Sangamo Therapeutics Stock (SGMO)